These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26524901)

  • 21. Pathophysiology of obesity hypertension.
    Hall JE
    Curr Hypertens Rep; 2000 Apr; 2(2):139-47. PubMed ID: 10981140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modifications to central neural circuitry during heart failure.
    Weiss ML; Kenney MJ; Musch TI; Patel KP
    Acta Physiol Scand; 2003 Jan; 177(1):57-67. PubMed ID: 12492779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenesis of hypertension in renal failure: role of the sympathetic nervous system and renal afferents.
    Phillips JK
    Clin Exp Pharmacol Physiol; 2005; 32(5-6):415-8. PubMed ID: 15854151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Stress and dietary salt intake in the pathogenesis of hypertension: role of the renal and sympathetic nervous system].
    Lin ST; Zou WQ; Chen J; Li P
    Sheng Li Xue Bao; 1999 Feb; 51(1):7-13. PubMed ID: 11972168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of hypertension in obesity.
    Dornfeld LP; Maxwell MH; Waks A; Tuck M
    Kidney Int Suppl; 1987 Oct; 22():S254-8. PubMed ID: 3323617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sympathetic Nervous System Contributions to Hypertension: Updates and Therapeutic Relevance.
    DeLalio LJ; Sved AF; Stocker SD
    Can J Cardiol; 2020 May; 36(5):712-720. PubMed ID: 32389344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reactive oxygen species and the central nervous system in salt-sensitive hypertension: possible relationship with obesity-induced hypertension.
    Ando K; Fujita M
    Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):111-6. PubMed ID: 21388436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired baroreflex sensitivity and responses to angiotensin converting enzyme inhibitor in salt-induced hypertension and its prevention by dietary calcium supplement in Sprague-Dawley rats.
    Ladipo CO; Egbe PE; Ibu JO
    Afr J Med Med Sci; 2006 Mar; 35(1):29-36. PubMed ID: 17209324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders.
    Magill SB
    Compr Physiol; 2014 Jul; 4(3):1083-119. PubMed ID: 24944031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
    Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
    Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The kidney and the neurogenic control of blood pressure in renal disease.
    Campese VM
    J Nephrol; 2000; 13(3):221-4. PubMed ID: 10928299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the sympathetic nervous system in obesity-related hypertension.
    da Silva AA; do Carmo J; Dubinion J; Hall JE
    Curr Hypertens Rep; 2009 Jun; 11(3):206-11. PubMed ID: 19442330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Remodeling of central sympathetic circuits precedes the development of hypertension.
    Murphy MN
    J Appl Physiol (1985); 2010 Dec; 109(6):2011-2. PubMed ID: 21188827
    [No Abstract]   [Full Text] [Related]  

  • 34. Withdrawal of endogenous sympathetic drive lowers blood pressure in primary aldosteronism.
    Nicholls MG; Julius S; Zweifler AJ
    Clin Endocrinol (Oxf); 1981 Sep; 15(3):253-8. PubMed ID: 6975670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The sympathetic nervous system in obesity hypertension.
    Lohmeier TE; Iliescu R
    Curr Hypertens Rep; 2013 Aug; 15(4):409-16. PubMed ID: 23677623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension.
    Engeli S; Sharma AM
    J Mol Med (Berl); 2001; 79(1):21-9. PubMed ID: 11327100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathophysiology of essential hypertension: an update.
    Saxena T; Ali AO; Saxena M
    Expert Rev Cardiovasc Ther; 2018 Dec; 16(12):879-887. PubMed ID: 30354851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity and hypertension.
    El-Atat F; Aneja A; Mcfarlane S; Sowers J
    Endocrinol Metab Clin North Am; 2003 Dec; 32(4):823-54. PubMed ID: 14711064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurovascular mechanisms and sodium balance in the pathogenesis of hypertension.
    Brum JM; Tramposch AF; Ferrario CM
    Hypertension; 1991 Jan; 17(1 Suppl):I45-51. PubMed ID: 1987011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental hypertension.
    Bohr DF; Dominiczak AF
    Hypertension; 1991 Jan; 17(1 Suppl):I39-44. PubMed ID: 1846123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.